<DOC>
	<DOCNO>NCT00237354</DOCNO>
	<brief_summary>The objective study investigate safety intralesional ( IL ) PV-10 treatment recurrent breast carcinoma . This study also include preliminary assessment response inject lesion histologic assessment upon lesion excision 1-3 week follow IL PV-10 administration . Post-excision wound heal assess clinically 1 week 4 week follow excision PV-10 injected lesion .</brief_summary>
	<brief_title>PV-10 Chemoablation Recurrent Breast Carcinoma</brief_title>
	<detailed_description>This single center , open label , ascend dose study . Subjects least one recurrent , histologically confirm measurable soft tissue breast carcinoma candidate lumpectomy ( removal lesion site recurrence breast another site ) mastectomy receive single intralesional injection PV-10 single target lesion uniformly infiltrate target lesion 0.5 cm margin dose 1.0 mL/cc lesion volume . Systemic locoregional adverse event monitor study interval . Subject accrual PV-10 administration stop 1 subject treatment relate Grade 3 non-hematological Grade 4 hematological toxicity within period two week PV-10 administration .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Biopsy confirm recurrent soft tissue breast carcinoma At least one measurable target lesion least 0.5 cm 3 cm long diameter Performance Status : Karnofsky 70100 % ECOG 02 Life Expectancy : At least 6 month Hematopoietic : White blood cell count ( WBC ) least 3000/mm3 Absolute neutrophil count ( ANC ) least 1.5 ( 1,500/mm3 ) Hemoglobin least 10 g/dL Platelet count least 100,000/mm3 Coagulopathy : International Normalized Ratio ( INR ) least 1.5 . Renal Function : Creatinine = 0.050.11 mmol/L Hepatic Function : Bilirubin = 321 umol/L AST/ALT â‰¤ 3 time upper limit normal ( ULN ) Cardiovascular Function : No major cardiovascular disease Thyroid Function : T3 ( serum triiodothyronine ) , T4 ( serum thyroxine ) THS ( serum thyrotropin ) within normal limit Immunological Function : Adequate immune system function opinion investigator Radiation therapy study lesion within 4 week Chemotherapy systemic cancer therapy within 4 week ( 6 week nitrosoureas mitomycin ) Local treatment ( e.g. , surgery , cryotherapy , radiofrequency ablation ) treatment area within 4 week Investigational agent within 4 week ( 5 halflives ) Antitumor vaccine therapy within 12 week Concurrent illness : Severe diabetes extremity complication due diabetes Significant concurrent disease illness , psychiatric disorder , alcohol chemical dependence would , opinion investigator , compromise subject safety compliance interfere interpretation study result Thyroid autoregulatory dysfunction , include thyroid disease ( subclinical ongoing ) , goiter , partial thyroidectomy , prior radioiodine surgicallytreated Graves ' hyperthyroidism , cystic fibrosis Pregnancy fertile female subject use effective contraception , lactate Known suspect brain metastasis spinal cord compression .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Recurrent soft tissue breast carcinoma</keyword>
</DOC>